Preparation, characterization and pharmacokinetics of liposomes- encapsulated cyclodextrins inclusion complexes for hydrophobic drugs

Drug Delivery

Volumn 14, Issue 4, 2007, Pages 201-208

  Chen, Hailiang ^a   Gao, Jianqing ^a   Wang, Fei ^b   Liang, Wenquan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Cyclodextrins; Inclusion Complexes; Liposomes; Pharmacokinetics Indomathacin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; INDOMETACIN; LIPOSOME;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; EXPERIMENTAL RABBIT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHOBICITY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SLOW DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; FEASIBILITY STUDIES; HYDROPHOBICITY; INDOMETHACIN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LIPOSOMES; MODELS, BIOLOGICAL; RABBITS; SOLUBILITY;

EID: 34248569611     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540601036880     Document Type: Article

References (29)

1. Allen, T. M. 1998. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drug 56:747-56.
2. Banerjee, R. 2001. Liposomes: applications in medicine. J. Biomater. Appl. 16:3-21.
3. Davis, M. E., and Brewster, M. E. 2004. Cyclodextrin-based pharmaceutics: Past, present and future. Nat. Rev. Drug Discov. 12:1023-1035.
4. Duchene, D., Ponchel, G., and Wouessidjewe, D. 1999. Cyclodextrins in targeting application to nanoparticles. Adv. Drug Del. Rev. 36:29-40.
5. Fatouros, D. G., Hatzidimitriou, K., and Antimisiaris, S. G. 2001. Liposomes encapsulating predinisolone and predinisolone-cyclodextrin complexes: Comparison of menbranes interity and drug release. Eur. J. Pharm. Sci. 13:287-296.
6. Gabizon, A., Shmeeda, H., and Barenholz, Y. 2003. Pharmacokinetics of pegylated liposomal doxorubin: Review of animal and human sutides. Clin. Pharmacokin. 42:419-436.
7. Higuchi, T., and Connors. K. 1965. A phase solubility technique. Adv. Anal. Chem. Instrum (New York) 4:117-211.
8. Immordino, M. L., Brusa, P., Arpicco, S., Stella, B., Dosio, F., and Cattel, L. 2003. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control Rel. 91:417-429.
9. Kim, S. Y., Lee, Y. M., and Kang, J. S. 2005. Indomethacin-loaded methoxy poly(ethylene glycol)/poly(D,L-lactide) amphiphilic diblock copolymeric nanospheres: Pharmacokinetic and toxicity studies in rodents. J. Biomed. Mater. Res. A 74:581-590.
10. Kirby, C., and Gregoriadis, G. 1984. Dehydration-rehydration vesicles (DRV): A new method for high yield drug entrapment in liposomes. Biotechnology 2:979-984.
11. Loftsson, T., Jarhi, P., Masson, M., and Jarvinen, T. 2005. Cyclodextrins in drug delivery. 2:335-351.
12. Loukas, Y. L., Jayasekera, P. and Gregoriadis, G. 1995a. Novel liposome based multicomponent systems for the protection of photolabile agents. Int. J. Pharm. 117:85-94.
13. Loukas, Y. L., Vyza, A. E., Valiraki, A. P., and Gregoriadis, G. 1995b. Inclusion complexes and stability studies of organophosphorus insecticide with stability constant. Analyst. 120:533-538.
14. Loukas, Y. L., Vraka, V., and Gregoriadis, G. 1998. Drugs, in cylodextrins, in liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis. Int. J. Pharm. 162:137-142.
15. Maestrelli, F., Rodriguez, M. L. G., Rabasco, A. M., and Mura, P. 2005. Preparation and characterization of liposomes encapsulating ketoprofen- cyclodextrin complexes for transdermal drug delivery. Int. J. Pharm. 298:55-67.
16. McCormack, B., and Gregoriadis, G. 1994a. Drugs-in-cyclodextrins-in liposomes: A novel concept in drug delivery. Int. J. Pharm. 112:249-258.
17. McCormack, B., and Gregoriadis, G. 1994b. Entrapment of cyclodextrin-drug complexes into liposomes: Potential advantages in drug delivery. J. Drug Target 2:449-454.
18. Mesen, J. L., and Putterman, P. 1991. Pharmacologyical application of a - hydroxypropyl-β-cyclkodextrin. In: New Trends in Cyclodextrins and Derivatives. ed. Duchen, D., pp. 369-407, Paris: Editionds De Sante.
19. Michaelis, M., Zimmer, A., Handjou, N., Cinatl, J., and Cinatl, J. J. 2005. Increased systemic efficacy of aphidicolin encapsulated in liposomes. Oncol. Rep. 13:157-160.
20. Perkins, W. R., Ahmad, I., Li, X., Hirsh, D. J., Masters, G. R., Fecko C. J., Lee, J., et al. 2000. Novel therapeutic nano-particles (lipocores): Trapping poorly water soluble compounds. Int. J. Pharm. 200:27-39.
21. Phan, G., Herbet, A., Cholet, S., Benech, H., Deverre, J. R., and Fattal, E. 1997. Pharmacokinetics of DTPA entrapped in conventional and long-circulating liposomes of different size for plutonium decorporation. J. Control Rel. 110:177-188.
22. Sihorkar, V., and Vyas. S. P. 2001. Potential of polysaccharide anchored lipsomes in drug delivery, targeting and immunization. J. Pharm. Pharm. Sci. 4:138-158.
23. Skalko, B. N., Pavelic. Z., and Becirevic, L. M. 2000. Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev. Ind. Pharm. 26:1279-1284.
24. Takino, T., Konishi, K., Takakura, Y., and Hashida, M. 1994. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol. Pharm. Bull. 17:121-125.
25. Torchilin, V. P. 1985. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 2:65-115.
26. Tayyab, S., Haq, S. K., Aziz, S. M. A., Khan, M. M., and Muzammil, S. 1999. Effect of lysine modification on the conformation and indomethacin binding properties of human serum albumin. Int. J. Biol. Macro. 26:173-180.
27. Uekama, K. 2004. Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. 52:900-915.
28. Vandekerckhove, K., Macrae, D., and Slavik, Z. 2005. Nonsurgical treatment of patent arterial duct in term neonates with congenital heart disease: The role of intravenous indomethacin. Pediatr. Cardiol. 26:698-699.
29. Watanabe, K., Tomita, H., Ono, Y., Yamada, O., Kurosaki, K., and Echigo, S. 2003. Intravenous indomethacin therapy in infants with a patent ductus arteriosus complicating other congenital heart defects. Circ. J. 67:750-752.